Cannabis Rescheduling Announcement: What It Means for America

Today marks an important moment in federal cannabis policy.

The U.S. Department of Justice has moved certain FDA approved  cannabis derived medications into Schedule III under the Controlled Substances Act. This reflects growing federal recognition that cannabinoids have legitimate medical use and will become a part of the future of healthcare.

However, it’s important to understand what this does, and does not change.

What This Update Does

This change applies specifically to FDA-approved cannabinoid medications, which meet established standards for safety, efficacy, and prescribing. It may:

• Expand research opportunities for cannabis therapeutics
•  Reduce regulatory barriers for approved products
•  Support more formal integration into healthcare over time

What This Does NOT Change Yet

Most cannabis products used by patients today, including those purchased in state medical dispensaries, are not FDA-approved medications. They remain:

• Regulated at the state level through medical cannabis programs
•  Not yet prescribed through traditional pharmacy systems
•  Not typically covered by insurance reimbursement
•  Guided by dispensary staff, not medical providers

In other words: Dispensary products do not suddenly become “prescriptions” under this policy change. 

Why This Still Matters

Even though state programs remain unchanged, expectations are shifting.

As cannabis is more clearly recognized as medicine:

• Patients will ask more clinical questions on how cannabis can help them
  • Providers will face increasing pressure to respond with education and care
  • Documentation and safety considerations will become more important

This highlights a growing gap between patient use and clinical guidance.

A Step Forward, Not the Final Destination

This is not full federal legalization. But it is a meaningful step toward aligning federal policy with how cannabis is already being used in patient care.

It also reinforces something we see every day; Patients are not waiting for policy to catch up. Over 50 million Americans used cannabis at least once in the past year, and cannabis is becoming more accepted as a therapeutic tool.

We welcome meaningful progress in aligning federal policy with state-level medical programs, expanding research opportunities, and opening the door for more clinically grounded conversations around cannabinoid therapeutics. 

For more details on these changes, read the full breakdown from the National Organization for the Reform of Marijuana Laws (NORML): HERE 

What Comes Next

This moment raises important questions for clinicians, patients, and the broader healthcare system:

• How will cannabis be integrated into our current healthcare models?
  • What role will reimbursement and ACO structures play?
  • How do we ensure safe, informed use in the meantime?

We will continue to follow these developments closely and share updates as they unfold. Stay tuned to our newsletter for updates and progress for us all. 

Learn more:  DOJ Announcement Link
Check out our most recent blog:  From Curiosity to Clinical Confidence – Cannabis Nurse Health Coach Certificate Program 

With you on the journey,
The Holistic Caring & Green Nurse Team 
The Bloom Hemp CBD Team